EL-18· Research peptide
Selank
Batch analytics · >99 % purity
Illustrative image; appearance and packaging may vary. 10 unlabelled vials, labelled only on the kit packaging. The selected strength applies.
EL-18· Research peptide
Batch analytics · >99 % purity
Illustrative image; appearance and packaging may vary. 10 unlabelled vials, labelled only on the kit packaging. The selected strength applies.
No reviews yet. Be the first to share your experience.
Research Use Only (RUO)
Tier I · Synthesis QC
Tier I · Synthesis QC
In-house · per step
RP-HPLC, MS confirmation, sequence verification in cleanroom.
Tier II · In-process
Tier II · In-process
Batch · final
Identity, purity, and assay before release.
Tier III · Third-party lab
Tier III · Third-party lab
External · independent
HPLC, ICP-MS, and microbiology by accredited lab.
953
satisfied
99.41%
Avg. purity 2026
4.8 ★
Store rating
EL-18 · Reference data
Heptapeptid · Tuftsin-Analog
Selank is a synthetic peptide made up of seven amino acids that is studied in neuropharmacological research. Its sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro is precisely defined, making the compound interesting for studies of nerve cells and neurotransmitter systems. Particularly compelling is where molecular GABA research meets clinical observations in anxiety states.
Anxiety-related systems are a complex research field in which neurotransmitters, receptors and stress axes interact. With its short, defined structure, Selank offers a manageable starting point for examining individual levels of these systems in a targeted way.
The sequence can be broken down into its seven building blocks: threonine, lysine, proline, arginine, proline, glycine and proline. For research, this defined order matters because it creates a reproducible basis for experiments and makes the compound distinguishable from other peptides.
GABA is the main inhibitory neurotransmitter in the central nervous system. It tempers the excitability of nerve cells and helps keep signals organized in time and space. GABAergic systems include receptors, transporters and enzymes, and their interaction determines how strong an inhibitory effect is within a given network.
In a study in rats, Selank altered the expression of several genes involved in GABAergic neurotransmission. Part of the pattern resembled the changes seen after GABA administration (study of GABA-related gene expression). The measurements came from the frontal cortex and provide insight into how the peptide might influence signal processing at the molecular level.
Genes are the blueprints for receptors, transporters and enzymes. When their expression changes, a system's capacity changes, not just its current activity. That is precisely why transcriptional data provide an interesting entry point for asking how a peptide might shape GABAergic networks over the longer term.
Context still matters: findings from the rat brain do not demonstrate direct binding to benzodiazepine receptors or an increase in cognitive performance in humans. They provide a well-grounded mechanistic hypothesis that is being tested in additional models.
The key clinical study included 62 patients: 30 received Selank and 32 received the comparator drug Medazepam. In generalized anxiety disorder and neurasthenia, similar anxiolytic effects were reported on clinical rating scales for both groups (randomized comparison study with 62 patients).
The study was randomized and actively controlled. Placebo control and blinding are not described in the abstract, so similar scale scores are not formal evidence of non-inferiority or general equivalence. The results apply to adults with these two diagnoses in clinical care, not to other forms of anxiety or healthy individuals.
The same study measured enkephalin activity in serum and related it to anxiety and asthenia scores (the study's enkephalin measurements). Enkephalins are endogenous opioid peptides involved in regulating pain perception and emotional processing. Serum activity is an indirect measure and does not mirror one-to-one what happens in the brain. The observed associations are therefore an exploratory indication of possible systems involved, not proof of the mechanism of action.
Preclinical gene expression, clinical scale scores and enkephalin measurements describe different levels of the same research field. No level replaces another. Together they form a profile that makes Selank an interesting subject of study for anxiety-related neuropharmacology and provides starting points for further studies.
Selank is available as Selank 10 mg and Selank 5 mg; the figure refers to the amount per vial. For neuropharmacological studies, this gives you two clearly defined variants to choose from. Buy Selank now and view the matching variant in the shop.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.41% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is studied in neuropharmacological research in relation to anxiety states and GABAergic signaling pathways.
In rats, Selank altered the expression of several GABA-related genes, in part similarly to changes after GABA administration. The finding supports a mechanistic hypothesis; however, the study is not a receptor-binding study.
The randomized study included 62 adults: 30 received Selank and 32 received Medazepam. In generalized anxiety disorder and neurasthenia, similar scores were reported on clinical scales.
Enkephalins are endogenous opioid peptides involved in the processing of pain and emotion. The study related their serum activity to anxiety and asthenia scores, yielding an exploratory indication, not proof of a mechanism.